Novartis says revolade shows long-term disease control for chronic/persistent immune thrombocytopenia
ZURICH (Reuters) - Novartis said on Wednesday a long term study of its Revolade drug showed good results in treating chronic and persistent immune thrombocytopenia (ITP) - a condition where patients' blood does not clot normally.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news